{"id":10018,"date":"2020-06-25T15:56:22","date_gmt":"2020-06-25T10:26:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=10018"},"modified":"2023-08-17T10:50:35","modified_gmt":"2023-08-17T05:20:35","slug":"recent-pharma-happenings-for-regeneron-simcha-merck-yumanity","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity","title":{"rendered":"Regeneron&#8217;s I-O Drug; Gene Therapy for Parkinson&#8217;s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0f5cb76dcce\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0f5cb76dcce\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity\/#Regeneron_recognizes_new_combos_to_boost_I-O_drug_Libtayos_cancer_response\" >Regeneron recognizes new combos to boost I-O drug Libtayo&#8217;s cancer response<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity\/#Gene_therapy_eradicates_Parkinsons_symptoms_in_mouse_models\" >Gene therapy eradicates Parkinson&#8217;s symptoms in mouse models<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity\/#Merck_inks_USD_500_Million_Yumanity_agreement\" >Merck inks USD 500 Million Yumanity agreement&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity\/#Simcha_debuts_with_USD_25_Million_to_progress_custom-built_IL-18_for_cancer\" >Simcha debuts with USD 25 Million to progress custom-built IL-18 for cancer<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading advgb-dyn-dc23c552\"><span class=\"ez-toc-section\" id=\"Regeneron_recognizes_new_combos_to_boost_I-O_drug_Libtayos_cancer_response\"><\/span><strong>Regeneron recognizes new combos to boost I-O drug Libtayo&#8217;s cancer response<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>PD-1\/L1 inhibitors work by enhancing the immune response to <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\"><strong>cancer<\/strong><\/a>, have benefitted patients combat several types of tumors. However, many people either do not respond to these checkpoint inhibitors, or they eventually develop resistance to them.<\/p>\n\n\n\n<p>The scientists at Regeneron were searching for ways to enhance responses to PD-1 inhibitors, so they turned to bispecific antibodies that link the T cells of the immune system and tumour cells by binding to molecules present on cell surfaces.<\/p>\n\n\n\n<p>Regeneron showed that adding bispecific antibodies aiming a T cell protein called CD28 to its Sanofi-partnered PD-1 inhibitor Libtayo led to improved anti-tumour activity in multiple animal models and long-term T-cell memory against the tumors as published in Science Translational Medicine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-f3006978\"><span class=\"ez-toc-section\" id=\"Gene_therapy_eradicates_Parkinsons_symptoms_in_mouse_models\"><\/span><strong>Gene therapy eradicates Parkinson&#8217;s symptoms in mouse models<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A researcher at the University of San Diego, California (USCD) made an accidental discovery several years back after he silenced a gene called PTB in mouse fibroblasts, cells in connective tissue. Within weeks, the majority of all of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/fibroblast-activation-protein-fap-or-seprase-inhibitor-pipeline-insight\"><strong>fibroblasts <\/strong><\/a>were wiped out, and the rest had transformed into neurons.<\/p>\n\n\n\n<p>Now, researchers are using the discovery to <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><strong>Parkinson&#8217;s disease<\/strong><\/a> in the anticipations of creating a one-time gene therapy to restore the dopamine-producing neurons, which are lost to the disease.<\/p>\n\n\n\n<p>The UCSD team created a <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-in-oncology-innovation-to-commercialization-competitive-landscape\"><strong>gene therapy<\/strong><\/a> technique, which impairs the ability of the PTB gene to produce a functioning protein. In mouse models of Parkinson&#8217;s, the gene therapy turned into supportive cells, also known as, astrocytes into dopamine-producing neurons, removing symptoms of the disease as reported by the researchers in the journal Nature.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-c9541406\"><span class=\"ez-toc-section\" id=\"Merck_inks_USD_500_Million_Yumanity_agreement\"><\/span><strong>Merck inks USD 500 Million Yumanity agreement&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Merck is penning USD 500 million-plus on a pact that looks it garner access to a neurodegenerative disease drugs of Yumanity.<\/p>\n\n\n\n<p>The U.S. Big Pharma grabs the exclusive rights for two preclinical assets aiming <a href=\"https:\/\/www.delveinsight.com\/report-store\/amyotrophic-lateral-sclerosis-als-market\"><strong>amyotrophic lateral sclerosis (ALS)<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/frontotemporal-dementia-market\"><strong>frontotemporal lobar dementia (FTLD)<\/strong><\/a>.<\/p>\n\n\n\n<p>FTLD is a group of uncommon brain disorders, which primarily impair the frontal and temporal lobes of the brain. These areas of the brain are, usually, associated with personality, behaviour and language.<\/p>\n\n\n\n<p>Whereas <a href=\"https:\/\/www.delveinsight.com\/report-store\/amyotrophic-lateral-sclerosis-als-epidemiology-forecast\"><strong>Amyotrophic Lateral Sclerosis<\/strong><\/a> causes a gradual deterioration and death of motor neurons, and will usually prove fatal.<\/p>\n\n\n\n<p>There are, presently, four drugs approved by the U.S. FDA for treatment of ALS are Radicava, Rilutek, Tiglutik and Nuedexta although none is curative.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-866e8e8b\"><span class=\"ez-toc-section\" id=\"Simcha_debuts_with_USD_25_Million_to_progress_custom-built_IL-18_for_cancer\"><\/span><strong>Simcha debuts with USD 25 Million to progress custom-built IL-18 for cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/cytokine-release-syndrome-market\"><strong>Cytokines<\/strong><\/a>, like interleukin-2, emerged as a promising treatment for cancer. They were the first modern drugs that proved the immune system could be aimed for cancer treatment.<\/p>\n\n\n\n<p>Now, the problem is that the cytokines evolved as signalling molecules and not as cancer drugs. Some functions can be beneficial, and others can be deadly and toxic, or even oppose the function.&nbsp;<\/p>\n\n\n\n<p>Native interleukins required to be given at high doses and can cause side effects such as immunosuppression and vascular leak, where fluids and proteins leak from blood vessels into surrounding tissues, leading to organ damage.&nbsp;<\/p>\n\n\n\n<p>Simcha intends to solve those problems, and others, by engineering cytokines with a deliberate therapeutic purpose and it has raised USD 25 million from WuXi AppTec, Sequoia Capital and Connecticut Innovations to do so. Its lead program is a custom-built IL-18 that overcomes hurdles faced by the native protein.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regeneron recognizes new combos to boost I-O drug Libtayo&#8217;s cancer response PD-1\/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patients combat several types of tumors. However, many people either do not respond to these checkpoint inhibitors, or they eventually develop resistance to them. The scientists at Regeneron were searching for ways [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10036,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[74,18488,349,395,16778,639,504,18489],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-10018","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-amyotrophic-lateral-sclerosis","tag-frontotemporal-lobar-dementia","tag-latest-pharma-news","tag-merck","tag-parkinsons-disease-4","tag-pharma-news","tag-regeneron","tag-simcha","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Regeneron, Yumanity, Merck, Simcha, USCD<\/title>\n<meta name=\"description\" content=\"Regeneron\u2019s I-O Drug; Gene Therapy for Parkinson\u2019s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Regeneron, Yumanity, Merck, Simcha, USCD\" \/>\n<meta property=\"og:description\" content=\"Regeneron\u2019s I-O Drug; Gene Therapy for Parkinson\u2019s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-25T10:26:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-17T05:20:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25180048\/News-1-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Regeneron, Yumanity, Merck, Simcha, USCD","description":"Regeneron\u2019s I-O Drug; Gene Therapy for Parkinson\u2019s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Regeneron, Yumanity, Merck, Simcha, USCD","og_description":"Regeneron\u2019s I-O Drug; Gene Therapy for Parkinson\u2019s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-06-25T10:26:22+00:00","article_modified_time":"2023-08-17T05:20:35+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25180048\/News-1-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity","name":"Pharma News | Regeneron, Yumanity, Merck, Simcha, USCD","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25180048\/News-1-1.jpg","datePublished":"2020-06-25T10:26:22+00:00","dateModified":"2023-08-17T05:20:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Regeneron\u2019s I-O Drug; Gene Therapy for Parkinson\u2019s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-regeneron-simcha-merck-yumanity#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25180048\/News-1-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25180048\/News-1-1.jpg","width":772,"height":482,"caption":"Pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/25180048\/News-1-1-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">amyotrophic lateral sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Frontotemporal Lobar Dementia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Simcha<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">amyotrophic lateral sclerosis<\/span>","<span class=\"advgb-post-tax-term\">Frontotemporal Lobar Dementia<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Regeneron<\/span>","<span class=\"advgb-post-tax-term\">Simcha<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 25, 2020","modified":"Updated on Aug 17, 2023"},"absolute_dates_time":{"created":"Posted on Jun 25, 2020 3:56 pm","modified":"Updated on Aug 17, 2023 10:50 am"},"featured_img_caption":"Pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=10018"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10018\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/10036"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=10018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=10018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=10018"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=10018"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=10018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}